Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
HUGO Series 🌟
HUGO-GT™ (Humanized Genomic Ortholog)
HUGO-Ab™ (Humanized Genomic Ortholog for Antibody)
MouseAtlas Model Library
Flash Sales
Research Models
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
Cell Line Models
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Services
Preclinical Efficacy
Neuroscience
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Models
Metabolic & Cardiovascular Diseases
Anti-Obesity
Autoimmune & Inflammatory
Genetically Engineered Animals
Knockout Mice
Transgenic Mice
Knockin Mice
Knockout Rats
Knockin Rats
Transgenic Rats
Model Generation Techniques
Turboknockout® Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Breeding & Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Modalities
Gene Therapy
AI-Powered AAV Discovery
Oligonucleotide Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
About Us
Corporate Overview
Facility Overview
Animal Health & Welfare
Health Reports
Our Team
Our Partners
Careers
Contact Us
Login
Neuroscience

PRKN Gene Function & Its Critical Role in Parkinson’s Pathogenesis

Cyagen Technical Content Team | July 09, 2025
Research-Ready Parkinson's Disease Mouse Models
Access KO/cKO models for PRKN, Lrrk2, and Pink1 to accelerate your PD drug discovery.
Research-Ready Parkinson's Disease Mouse Models
Contents
01. PRKN Gene Overview: Comparative Genomics (Human vs. Rodents) 02. Parkin Protein: E3 Ligase Mechanism and Pathogenic Mutations 03. Tissue-Specific Expression: Beyond Neurodegeneration 04. References

Parkinson's disease (PD) is a neurodegenerative disorder that affects behavior and motor skills. In this article, we review the background information, research insights, and applications related to PRKN, a pathogenic gene of PD.

PRKN Gene Overview: Comparative Genomics (Human vs. Rodents)

Species Human Mouse Rat
Chromosome 6 17 1
Full Length (bp) 1,380,386 5,876 6,536
mRNA (nt) 860\930 1,146 1,564
Number of exons 14 20 1
Number of amino acids 465 464 465
Gene Family NKIB1, RNF14, RNF19A, ARIH2, ARIH
Cyagen Mouse Models
Status Custom Catalog Models Live Mice
Knockout (KO) √ √
Conditional Knockout (cKO) √ √
Note: the mark “√” represents the corresponding models that available from Cyagen Knockout Catalog Models.

Parkin Protein: E3 Ligase Mechanism and Pathogenic Mutations

Parkin, encoded by PRKN gene, is one of the largest human genes with a length of 1.38 million bp. The Prkn gene in mice and rats is also around 1.2 million bp in length. The human Parkin protein, an E3 ubiquitin ligase consisting of 465 amino acids, is responsible for attaching ubiquitin, a signal described as “the molecular kiss of death” to the targeted protein for recognition and breakdown by the protease. The human PRKN protein does not have much difference in length compared to the protein in mice and rats, however, they vary greatly in major RNA derivatives of PRKN. The length of major transcripts in humans are almost 2.7 times that of rats. However, the number of amino acid bases in the protein is roughly the same across these species.

PRKN is a recessively inherited gene of Parkinson's disease (PD); in other words, humans develop PD only when the gene is recessively homozygous. Figure 1 shows different structures and mutations of Parkin protein. The item on the left represents ubiquitin binding region (UBL), followed by linker region (Linker), ring finger domain 0 (RING0) and typical RBR structure (RING1-IBR-RING2), where the REP structure contains rich cysteine.

Figure 1: Human mutation sites in the population, where the red represents pathogenic mutation sites, and black indicates unknown effect. DOI: 10.3233/JPD-160989.
Figure 2: Role of Parkin in Parkinson's disease and cancer. DOI: 10.1007/s12035-018-0879-1

Under normal circumstances, Parkin (PARK2) can label CyclinE and other proteins with ubiquitin, and guide proteases to degrade them. However, when the protein-coding gene mutation causes abnormalities in the protein, it will not be able to perform the function of ubiquitination normally, thus resulting in the aggregation of some cyclins and other functional proteins. Additionally, it may cause abnormal proliferation in cells with mitotic conditions and apoptosis in neurons without mitotic conditions (Figure 3).

Figure 3: Quoted from DOI: 10.1007/s12035-018-0879-1

Tissue-Specific Expression: Beyond Neurodegeneration

Figure 4: mRNA relative expression of PRKN gene in humans and mice.

The expression of this gene in brain tissue and testis is significantly higher than that in other tissues. In addition, the expression of this gene is also high in human heart and kidney, even higher than that in human brain, where such gene is used to be studied. The expression of this gene in human adrenal glands is higher than the average (the expression is expressed by the normalized relative value rather than the direct RPKM data; such comparison is only limited to the same species rather than in between mice and human). Source: NCBI.

Since the first pathogenic gene of PD was identified in the 1990s, an increasing importance has been attached to the genetic influence on in the pathogenesis of PD.

Find more PD related mouse models in our selection of research-ready Cyagen Knockout Catalog Models.

Mice model Status
Lrrk2 KO mice Cryopreserved sperm
Pink1 KO mice Cryopreserved sperm
Pink1 cKO mice Cryopreserved sperm
Park7 (DJ-1) KO mice Cryopreserved sperm
Park2 (PRKN) KO mice Cryopreserved sperm
Park2 (PRKN) cKO mice Cryopreserved sperm

References

1. Wahabi, K., Perwez, A. & Rizvi, M.A. Parkin in Parkinson’s Disease and Cancer: a Double-Edged Sword. Mol Neurobiol 55, 6788–6800 (2018). https://doi.org/10.1007/s12035-018-0879-1.

2. Truban, Dominika et al. ‘PINK1, Parkin, and Mitochondrial Quality Control: What Can We Learn About Parkinson’s Disease Pathobiology?’ 1 Jan. 2017 : 13 – 29.

3. Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in McGregor MM, Nelson AB. Circuit Mechanisms of Parkinson's Disease. Neuron. 2019;101(6):1042-1056.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
Breakthrough Glaucoma Research: Leveraging ANGPTL7 Humanized Models for Gene Therapy
Beyond the ApcMin Model: Advancing CRC Research with High-Fidelity Apc-KO Precision Models
AAV Modeling + ASO/siRNA: Revolutionizing Preclinical Drug Evaluation
DMD Gene Therapy Evolution: From Exon Skipping to Precision Humanized Models
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Models
HUGO-Ab™ (Humanized Genomic Ortholog for Antibody)HUGO-GT™ (Humanized Genomic Ortholog)MouseAtlas Model LibraryResearch Models
Services
NeuroscienceOphthalmologyOncologyMetabolic & Cardiovascular DiseasesAutoimmune & Inflammatory
About Us
Corporate OverviewFacility OverviewAnimal Health & WelfareHealth ReportsOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research